On January 10, 2023 Atavistik Bio, a biotechnology company focused on revolutionizing the discovery of new allosteric protein-metabolite interactions to develop novel small molecule drugs for cancer, inborn errors of metabolism and other serious diseases, reported that it has entered into a collaboration agreement with Plex Research, a company providing a novel artificial intelligence (AI)-powered drug discovery platform (Press release, Atavistik Bio, JAN 10, 2023, View Source [SID1234647392]). Atavistik Bio’s incorporation of Plex Research’s technology will enrich the informatics capabilities of its Atavistik Metabolite Protein Screening (AMPS) platform and accelerate its drug discovery pipeline.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Atavistik Bio’s scalable AMPS platform combines an extensive and continually expanding protein-metabolite database map ("the Interactome"), along with advanced informatics tools, deep expertise in chemistry, and computationally rich structure-based design to systematically identify and understand the role of protein-metabolite interactions across important biological and disease-relevant pathways to inform small molecule drug discovery.
Under the collaboration, Atavistik Bio will enhance its proprietary Interactome map with Plex Research’s cloud-based AI-powered drug discovery search engine of large and disparate data sources to reveal hidden connections between related metabolites and ligands, pathways, biomarkers, and disease-relevant biology. The integration of Atavistik Bio’s AMPS data with Plex Research’s platform will create a unique and customizable data analysis engine to rapidly enable novel insights for drug discovery.
"Allosteric interactions, which we know can present novel druggable nodes for intractable targets, historically have been difficult to discover. Using our AMPS platform, we are able to systematically and rapidly interrogate protein-metabolite interactions to reveal new, disease-relevant allosteric binding sites," said Marion Dorsch, Ph.D., Atavistik Bio’s President and Chief Scientific Officer. "Fusing the enterprise-level capability of Plex’s access to large public databases with Atavistik’s proprietary data infrastructure has the potential to significantly augment the power of our AMPS platform and accelerate our efforts to drive the discovery of novel therapeutics for unmet patient needs."
"Atavistik’s platform creates opportunities to drug proteins in new ways by uncovering previously unknown regulatory sites with potentially important roles in disease," said Doug Selinger, President and CEO of Plex Research. "The breadth and depth of the Plex platform will provide important context for Atavistik’s AMPS data, which will enable better characterization of putative protein regulatory sites, ligand binding, and potential impacts on disease processes. The synergies between our technology platforms are compelling, and we’re excited to see where it will take us."